A novel process for the production of our lead investigational product SBP-101, reduces the number of synthetic steps for its production from seventeen to six, and provides patent coverage to 2039. Issue Notification for patent US 11,098,005 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”. Median overall survival for cohort 4 plus phase 1b (N=29) has not yet been reached. The third quarter 2021 was marked by further meaningful clinical progress.ġ6 patients are in survival follow up since enrollment completed in December 2020, with 2 patients from cohort 2 now exceeding 26.9 and 28.7 months. Management is hosting an earnings call today at 4:30 p.m. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today provided a business update and reported financial results for the quarter ended September 30, 2021. 10, 2021 (GLOBE NEWSWIRE) - Panbela Therapeutics, Inc.
0 Comments
Leave a Reply. |